• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Argenx Se ADR (NQ: ARGX )

    586.30 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, Oct 31, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Argenx Se ADR

    < Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
    Argenx Stock Crashes On An Unexpected Failure For Its Biggest Drug
    The company was hoping its drug would make a difference for patients with a rare blood disorder. 
    Via Investor's Business Daily
    These 2 Stocks Are Falling in a Fading Rally
    It's been a good month, but the stock market's looking tired. 
    Via The Motley Fool
    Why SpringWorks Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
    Shares of SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) surged in pre-market trading after the company reported the FDA approval of OGSIVEO (nirogacestat) as the first and only treatment for adults... 
    Via Benzinga
    Exposures Product Safety
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
    It's time to dive into the biggest pre-market stock movers for Tuesday morning with all of the latest news you need to know today! 
    Via InvestorPlace
    $1000 Invested In argenx 5 Years Ago Would Be Worth This Much Today
    Via Benzinga
    $1000 Invested In This Stock 5 Years Ago Would Be Worth $5,000 Today
    Via Benzinga
    Earnings Outlook For argenx
    Via Benzinga
    Zscaler Posts Q1 Results, Joins argenx, Cool Company And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
    U.S. stock futures traded mixed this morning, with the Dow Jones futures gaining around 15 points on Tuesday. 
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    argenx Reports Topline Results from ADVANCE-SC Study of VYVGART Hytrulo in Primary Immune Thrombocytopenia
    From argenx SE
    Via GlobeNewswire
    Antibody Player Dianthus Therapeutics Has Potential Amid Active M&A Landscape in Complement-Focused Firms: Analyst
    Wedbush initiated coverage on Dianthus Therapeutics Inc (NASDAQ: DNTH), noting its lead program DNTH103 as a well-positioned monoclonal antibody directed against the active form of the  
    Via Benzinga
    argenx Announces European Commission Approval of Subcutaneous VYVGART® (efgartigimod alfa) for Generalized Myasthenia Gravis
    From argenx SE
    Via GlobeNewswire
    Here's How Much You Would Have Made Owning argenx Stock In The Last 5 Years
    Via Benzinga
    Here's How Much You Would Have Made Owning argenx Stock In The Last 5 Years
    Via Benzinga
    The Latest Analyst Ratings for argenx
    Via Benzinga
    Tech Titans Rising: 7 Underrated Stocks Set for Explosive Growth
    Are you looking to invest in rising tech stocks? Here are seven underrated stocks set for explosive growth. 
    Via InvestorPlace
    Stock Market Rally Back In Force As Treasury Yields Plunge; Arista, Palantir Among Winners: Weekly Review
    Bulls are back in control as the major indexes confirmed the uptrend this week. 
    Via Investor's Business Daily
    argenx Highlights Data Evaluating VYVGART in Neuromuscular Autoimmune Disease at AANEM and MGFA Scientific Sessions
    From argenx SE
    Via GlobeNewswire
    argenx to Present at Upcoming Investor Conferences
    From argenx SE
    Via GlobeNewswire
    Argenx Comes Up With Big Sales Beat, Narrower-Than-Expected Losses
    The company sells Vyvgart, a treatment for generalized myasthenia gravis. 
    Via Investor's Business Daily
    Topics Earnings
    Exposures Financial
    argenx Reports Third Quarter 2023 Financial Results and Provides Business Update
    From argenx SE
    Via GlobeNewswire
    argenx to Report Third Quarter 2023 Financial Results and Business Update on October 31, 2023
    From argenx SE
    Via GlobeNewswire
    Stock Market Rally Attempt Underway; Micron, Nike, Amazon, Meta In Focus: Weekly Review
    But it's not a confirmed uptrend yet. Nike, Amazon and Meta were in focus. 
    Via Investor's Business Daily
    What's Going On Pfizer's Subsidiary Biohaven Stock?
    Pfizer Inc's (NYSE: PFE) subsidiary Biohaven Ltd (NYSE: BHVN) released an  
    Via Benzinga
    Biohaven, Yet Another Argenx Rival In Autoimmune Drugs, Just Rocketed 29%
    The companies hope by lowering immunoglobulin G, an antibody, that they can treat myriad autoimmune diseases. 
    Via Investor's Business Daily
    Why Immunovant Stock Is Bolting Higher Today
    The company may have best-in-class autoimmune disease therapy under its roof. 
    Via The Motley Fool
    Immunovant Parlays Its Shot At Rivaling Argenx Into A $300 Million Offering
    Both companies are working on drugs that lower an antibody tied to numerous autoimmune conditions. 
    Via Investor's Business Daily
    Immunovant Soars 73% — And Slugs Argenx — As Autoimmune Disease Battle Heats Up
    Immunovant is hoping to come up with the best drug in its class, lowering a key antibody tied to autoimmune diseases. 
    Via Investor's Business Daily
    Argenx's 28% Surge & Promising Product Propel Investor Confidence
    Argenx's chart is forming a bullish base after a 28% jump after positive clinical trials. Analysts believe the immunology specialist is an acquisition target. 
    Via MarketBeat
    argenx Announces VYVGART (efgartigimod alfa) Authorized for Sale by Health Canada for Generalized Myasthenia Gravis
    From argenx SE
    Via GlobeNewswire
    This New S&P 500 Entrant Leads 5 Stocks Near Buy Points
    These stocks could lead if the market rallies. 
    Via Investor's Business Daily
    Topics Stocks
    Exposures US Equities
    < Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.